Showing results (531-540 of 555) with videos related to
Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2021
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate CancerSamuel R Denmeade, Hao Wang, Neeraj Agarwal, et al.JCO Oncology Practice|September 28, 2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTCBrittany M Szymaniak, Lauren A Facchini, Veda N Giri, et al.BMC Cancer|June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA TrialPhuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.European Urology Open Science|December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.Biorxiv : the Preprint Server for Biology|August 12, 2025
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancerJohn T Phoenix, Audris Budreika, Devin A Schmeck, et al.The Prostate|December 24, 2022
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamideMaría P Fernandez-Perez, Enrique Perez-Navarro, Teresa Alonso-Gordoa, et al.European Journal of Cancer (Oxford, England : 1990)|March 27, 2023
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriersRebeca Lozano, Elena Castro, Fernando Lopez-Campos, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 5, 2021
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021Edward Schaeffer, Sandy Srinivas, Emmanuel S Antonarakis, et al.Pageof 56